VALUE OF RAPID CARBAPENEMASE DETECTION AND ITS ASSOCIATION WITH CEFTAZIDIME/AVIBACTAM RESISTANCE IN GRAM-NEGATIVE BACTERIA AT THANH NHAN HOSPITAL, 2025

Thị Vũ Nga Lưu, Thị Thanh Hoa Nguyễn

Main Article Content

Abstract

Objectives: To identify common carbapenemase types using the O.K.N.V.I RESIST-5 and RESIST-ACINETO rapid tests, and to describe the association between carbapenemase types and ceftazidime/ avibactam (CZA) resistance phenotypes among Gram-negative bacteria isolated at Thanh Nhan Hospital in 2025. Methods: A cross-sectional study was conducted on 150 Gram-negative isolates (Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii), including 120 carbapenem-resistant and 30 carbapenem-susceptible strains. Carbapenemase types (KPC, NDM, VIM, OXA-48, OXA-23/40/58) were detected using RESIST-5 and RESIST-ACINETO. CZA susceptibility was determined by automated systems and broth microdilution. Results: Carbapenemase positivity was 89.2% in carbapenem-resistant strains and 10% in susceptible strains (p < 0.001). In K. pneumoniae, OXA-48 predominated (56.8%), followed by KPC (45.9%) and NDM (37.8%). In P. aeruginosa, KPC (59%) and NDM (43.6%) were the main enzymes. A. baumannii primarily carried OXA-23 (77.3%). NDM strongly predicted CZA resistance in both P. aeruginosa (PPV 91.7%; OR = 13.75; p < 0.01) and K. pneumoniae (PPV 100%; OR = ∞). Conversely, KPC was associated with CZA susceptibility in K. pneumoniae (PPV 80%; OR = 0.125; p < 0.01) and P. aeruginosa (PPV 78.9%; OR = 0.014; p < 0.01). Conclusions: Rapid carbapenemase detection provides valuable guidance in the early selection of CZA before routine susceptibility results are available. The strong correlation between carbapenemase type and CZA phenotype highlights the clinical importance of rapid enzyme detection in optimizing antimicrobial therapy and infection control.

Article Details

References

World Health Organization (WHO). WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: WHO; 2024. Available from: https://www.who.int/ publications/i/item/9789240093461.
2. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA, et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2024; ciae403. doi: 10.1093/cid/ciae403.
3. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 35th ed. CLSI supplement M100. 2025.
4. CorisBio. O.K.N.V.I RESIST-5 product information and instructions for use. 2024. Available from: https://www.corisbio.com/ products/oknvi-resist-5.
5. Nguyễn Thị Lan Hương, Phạm Hồng Nhung. Xác định mức độ nhạy cảm kháng sinh và kiểu gene carbapenemase của một số vi khuẩn Klebsiella pneumoniae phân lập từ bệnh phẩm đường hô hấp và ổ bụng tại Bệnh viện Bạch Mai năm 2022 - 2023. Tạp chí Nghiên cứu Y học, 2025. 187(2): p. 22-30.
6. Lê Thanh Phong, Nguyễn Thị Hải Yến, Lê Minh Nhân, Nguyễn Thị Bé Hai, Bạch Thị Kiêu, Trần Hồng Phong, et al. Nghiên cứu tình hình đề kháng kháng sinh carbapenem và sự đột biến gen KPC, OXA-48 ở chủng Klebsiella pneumoniae phân lập tại Bệnh viện Đa khoa Hoàn Mỹ Cửu Long năm 2024–2025. Tạp chí Y học Việt Nam. 2025;550(2).
7. Ababneh, Q., et al., Predominance of extensively-drug resistant Acinetobacter baumannii carrying bla OXA-23 in Jordanian patients admitted to the intensive care units. PLoS One, 2025. 20(2): p. e0317798.
8. Trịnh Văn Sơn, Nguyễn Đăng Mạnh, Đào Thanh Quyên, Nguyễn Thị Kim Phương, Lê Hữu Song. Giá trị của kiểu gen trong xác định Klebsiella pneumoniae kháng carbapenem gây nhiễm khuẩn huyết. Y Dược học lâm sàng 108. 2020;15(4)